

Atezolizumab IMbrave150

PRELIMINARY SCORE

CURATIVE




NON-CURATIVE



ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Other adjustments



Atezolizumab IMbrave150

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
Therapeutic Indication: Advanced or unresectable hepatocellular carcinoma (HCC)  
who have not received prior systemic therapy  
Experimental Arm: Atezolizumab + Bevacizumab  
Control Arm: Sorafenib

